drugset
drugset / Trial / NCT02235727

Safety and Tolerability of GBR 900 in a Single Ascending Dose Study in Healthy Subjects

NCT02235727 ↗

Phase 1 Completed 37 enrolled Glenmark Pharmaceuticals Ltd. India Glenmark Pharmaceuticals S.A. · collab
RandomizedParallel-groupQuadruple-blindBasic science

Summary

A Single Dose Study of GBR 900 in Healthy Volunteers.

Timeline

Start
2014-07
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject GBR 900 Unknown — —

Indications

No indication recorded.